{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T11:21:38Z","timestamp":1778152898988,"version":"3.51.4"},"reference-count":23,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2013,4]]},"DOI":"10.1016\/j.ijrobp.2012.09.030","type":"journal-article","created":{"date-parts":[[2012,11,22]],"date-time":"2012-11-22T15:30:41Z","timestamp":1353598241000},"page":"1275-1281","source":"Crossref","is-referenced-by-count":57,"title":["Phase 1 Study of Erlotinib Plus Radiation Therapy in Patients With Advanced Cutaneous Squamous Cell Carcinoma"],"prefix":"10.1016","volume":"85","author":[{"given":"C. Hope","family":"Heath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas L.","family":"Deep","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisle","family":"Nabell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee","family":"Desmond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Clemons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Scott","family":"Magnuson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eben L.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2012.09.030_bib1","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJM200103293441306","article-title":"Cutaneous squamous-cell carcinoma","volume":"344","author":"Alam","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib2","doi-asserted-by":"crossref","first-page":"972497","DOI":"10.1155\/2011\/972497","article-title":"Outcomes of recurrent head and neck cutaneous squamous cell carcinoma","volume":"2011","author":"Dean","year":"2011","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.radonc.2004.07.007","article-title":"Targeting the epidermal growth factor receptor in radiotherapy: Radiobiological mechanisms, preclinical and clinical results","volume":"72","author":"Baumann","year":"2004","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/hed.21802","article-title":"EGFR expression in advanced head and neck cutaneous squamous cell carcinoma","volume":"34","author":"Sweeny","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib5","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1365-2133.2005.06709.x","article-title":"Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma","volume":"153","author":"Baltaci","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib6","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1200\/JCO.2009.27.0397","article-title":"Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer","volume":"28","author":"Cohen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib7","first-page":"269","article-title":"Phase II prospective trial of gefitinib given concurrently with cisplatin and radiotherapy in patients with locally advanced head and neck cancer","volume":"39","author":"Saarilahti","year":"2010","journal-title":"J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib8","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1245\/s10434-010-1009-0","article-title":"Improvements in the staging of cutaneous squamous-cell carcinoma in the 7th edition of the AJCC Cancer Staging Manual","volume":"17","author":"Lardaro","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib9","first-page":"806","article-title":"Incidence of incomplete excision in surgically treated cutaneous squamous cell carcinoma and identification of the related risk factors","volume":"49","author":"Mirshams","year":"2011","journal-title":"Acta Med Iranica"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib10","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","article-title":"Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme","volume":"98","author":"Peereboom","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib11","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1002\/cncr.24265","article-title":"Neoadjuvant chemotherapy\/gefitinib followed by concurrent chemotherapy\/radiation therapy\/gefitinib for patients with locally advanced squamous carcinoma of the head and neck","volume":"115","author":"Hainsworth","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib12","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1158\/1078-0432.CCR-11-1951","article-title":"A Phase II Study of Gefitinib for Aggressive Cutaneous Squamous Cell Carcinoma of the Head and Neck","volume":"18","author":"Lewis","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","article-title":"Skin toxicities associated with epidermal growth factor receptor inhibitors","volume":"4","author":"Li","year":"2009","journal-title":"Target Oncol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib14","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaad.2006.04.062","article-title":"Description and management of cutaneous side effects during cetuximab or erlotinib treatments: A prospective study of 30 patients","volume":"55","author":"Roe","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1200\/JCO.2004.06.075","article-title":"Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck","volume":"22","author":"Soulieres","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib16","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib17","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib18","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0360-3016(00)00663-5","article-title":"A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003","volume":"48","author":"Fu","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib19","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1440-1673.2005.01496.x","article-title":"Treatment recommendations in patients diagnosed with high-risk cutaneous squamous cell carcinoma","volume":"49","author":"Veness","year":"2005","journal-title":"Australas Radiol"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib20","article-title":"Early postoperative epidermal growth factor receptor inhibition: Safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in\u00a0vivo","author":"Sano","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib21","doi-asserted-by":"crossref","first-page":"257","DOI":"10.7150\/jca.3491","article-title":"Cetuximab in refractory skin cancer treatment","volume":"3","author":"Kalapurakal","year":"2012","journal-title":"J Cancer"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib22","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1002\/cncr.25786","article-title":"Phase I trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer","volume":"117","author":"Kao","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2012.09.030_bib23","doi-asserted-by":"crossref","first-page":"4880","DOI":"10.1200\/JCO.2007.12.9650","article-title":"Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer","volume":"25","author":"Chen","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301612036383?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301612036383?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,21]],"date-time":"2018-10-21T02:30:06Z","timestamp":1540089006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301612036383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["S0360301612036383"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2012.09.030","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4]]}}}